Changes in height in subgroups of patients
receiving growth hormone treatment. Values are means (SD) unless
otherwise specified
Treatment completed as scheduled
Treatment
stopped early
Baseline:
No (% boys) of
patients
1524 (56)**
1328 (74)
Age
(years)
12.9 (2.1)**
12.3 (2.3)
No (% boys)
prepubertal
881 (55)**
974 (72)
No pubertal
boys
371
287
No pubertal girls
272
67
Bone age
(years)
10.6 (2.2)**
9.8 (2.4)
Height (SD score)
2.7
(0.8)
2.7 (0.8)
Weight (SD score)
1.4
(0.9)*
1.6 (0.8)
Growth velocity (cm/year)
4.8
(1.8)**
4.4 (1.5)
Peak GH concentration (µg/l)
8.5
(3.6)*
8.8 (3.5)
Target height (SD score)
1.1
(1)
1.2 (1)
End of treatment:
No
1524
1328
Age (years)
16.6 (1.5)
15 (2.1)
Duration of treatment
(years)
3.6 (1.4)
2.7 (1.4)
Height (SD score)
1.7
(0.8)
2.1 (0.9)
Height (cm) (boys/girls)
163 (6)/151
(5)
152 (11)/141 (10)
Change in height (SD score)
1.0
(0.7)
0.6 (0.6)
Adult height:
No (% of patients at
baseline)
1232 (81)
933 (70)
Age (years)
20.8
(2.9)
20.9 (2.6)
Total duration of follow up (years)
7.9
(2.2)
8.5 (1.7)
Height (SD score)
1.6 (0.9)
1.5
(1)
Height (cm, boys/girls)
167 (6)/154 (5)
167 (6)/154 (6)
Change in height from end of treatment (SD score)
0.1
(0.5)
0.4 (0.9)
Change in height from baseline (SD
score)
1.1 (0.9)
1.1 (1)
SD=standard deviation.
Comparisons at baseline with patients who stopped treatment early
(Student's t test and Kruskall-Wallis test for peak GH,
P<0.01 considered to be significant, given the number of comparisons
performed): *P<0.001; **P<0.0001.
2.7
(0.8)
